Virpax Pharmaceuticals, Inc. (OTCPK: VRPX)
Health Care · Pharmaceuticals · US
$0.00
+100.00% today · -98.2% 1Y
Virpax Pharmaceuticals, Inc. (OTCPK: VRPX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $249.00 and employs 2 people.
Over the last twelve months the share price has lost 98.2%, trading between 0.00 and 0.10.
Tweenvest scores Virpax Pharmaceuticals, Inc. across four factors: quality 16/100. Its strongest factor is quality.
VRPX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $249.00
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -70.91
- Dividend yield
- —
- Beta (5Y)
- -16.32
- 52-week high
- $0.10
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 1.24M
- Employees
- 2
- Next earnings
- —
About Virpax Pharmaceuticals, Inc.
Virpax Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical enterprise, dedicated to pioneering diverse drug-delivery systems and novel drug-releasing technologies. Its core focus lies in developing advanced, non-opioid and non-addictive solutions for pain management, alongside therapies targeting central nervous system disorders. The company's current investigational pipeline features several preclinical product candidates. These include Epoladerm, a topical nonsteroidal anti-inflammatory drug (NSAID) designed to address chronic osteoarthritis of the knee, and Probudur, an injectable liposomal gel formulated as a local anesthetic for managing post-operative pain. Also in development are Envelta and PES200, both nanotechnology-based intranasal spray drug candidates engineered to deliver metabolically labile peptide drugs directly to the brain. Further candidates comprise AnQlar, an antiviral barrier solution intended to prevent or lessen the severity of human viral infections such as influenza and SARS-CoV-2, and VRP324, an experimental nasal formulation aimed at enhancing the transport of cannabidiol into the brain. Virpax Pharmaceuticals, Inc. was established in 2016 and is based in Berwyn, Pennsylvania.
- ISIN
- US9282513053
- Founded
- 2016
- Listed since
- Feb 17, 2021
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,246.93 | -0.67% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.04 | +1.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.66 | -1.24% |
| Roche Holding AGSWX: ROP | $368.80B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.97 | -0.36% |
Figures last refreshed Aug 18, 2026.